Clinical trials: Hemostasis Change
COVID, Disseminated Intravascular Coagulation
Coagulation Changes Associated With COVID-19 Infection
This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
- Conditions
- COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
- Trial name
- NCT04460664
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HemoSonics LLC
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered…
- Trial name
- NCT05259839
- Testing
- Etentamig, Dexamethasone, Lenalidomide
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 283 people
- Sponsor
- AbbVie
Gene Mutations, Pseudoxanthoma Elasticum
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
The purpose of this study (Study INZ701-304 [ADAPT]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to…
- Conditions
- Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
- Trial name
- NCT06462547
- Testing
- INZ-701
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Inozyme Pharma
Multiple Myeloma
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter…
- Trial name
- NCT04570631
- Testing
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have…
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
- Trial name
- NCT06357754
- Testing
- Idecabtagene vicleucel, Lisocabtagene maraleucel
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Relapsed or Refractory Multiple Myeloma
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available…
- Trial name
- NCT06825845
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 1,500 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.
- Trial name
- NCT06209606
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT07095452
- Testing
- Etentamig, Lenalidomide, Daratumumab
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 680 people
- Sponsor
- AbbVie
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in…
- Trial name
- NCT06896916
- Testing
- Etentamig, Iberdomide
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
B-cell Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
B-cell cancer is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT04804254
- Testing
- ABBV-623, ABBV-992
- Where
- 5 sites in Israel, Puerto Rico and 1 more
- Volunteers
- 5 people
- Sponsor
- AbbVie
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Indication for Modification of Patient Physical Status
Vela China Study: in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population
Prospective, multicenter, single-arm, non-controlled, 60 subjects enrolled and 14 days follow up for evaluate the safety and utility of VelaTM XL thulium laser.
- Trial name
- NCT02636738
- Testing
- Vela XL thulium laser, laser fiber and accessories.
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult…
- Trial name
- NCT06953960
- Testing
- Surzetoclax, Daratumumab, Dexamethasone
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Multiple Myeloma
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- NCT03875495
- Testing
- Temferon
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Genenta Science
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with…
- Trial name
- NCT05308654
- Testing
- ABBV-453, Dexamethasone, Daratumumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- AbbVie
Multiple Myeloma
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with…
- Trial name
- NCT04895410
- Testing
- Lemzoparlimab, Dexamethasone, Carfilzomib
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Lymphoplasmacytic Lymphoma (LPL) is a rare type of low-grade B-cell lymphoma. The purpose of this study is to assess the change in disease activity of adult participants with relapsed or refractory Waldenström…
- Trial name
- NCT07387471
- Testing
- Venetoclax
- Where
- 17 sites in Japan
- Volunteers
- 14 people
- Sponsor
- AbbVie